Discover the security impact of CVE-2018-14787 affecting Philips' IntelliSpace Cardiovascular products. Learn about the vulnerability, affected versions, and mitigation steps.
This CVE-2018-14787 article provides insights into a security vulnerability affecting Philips' IntelliSpace Cardiovascular (ISCV) products and Xcelera versions, potentially allowing unauthorized code execution.
Understanding CVE-2018-14787
This CVE involves improper privilege management in Philips' ISCV products, enabling attackers to access directories with executable files and run unauthorized code with local administrative privileges.
What is CVE-2018-14787?
An unauthorized individual with elevated privileges in Philips' ISCV products and Xcelera versions could exploit this vulnerability to access directories storing executable files, potentially leading to unauthorized code execution.
The Impact of CVE-2018-14787
The vulnerability could allow attackers to execute arbitrary code with local administrative permissions, posing a significant security risk to affected systems.
Technical Details of CVE-2018-14787
This section delves into the technical aspects of the CVE, including the vulnerability description, affected systems, and exploitation mechanism.
Vulnerability Description
The flaw in Philips' ISCV products and Xcelera versions allows attackers with escalated privileges to access folders containing executables, enabling them to execute unauthorized code with local administrative permissions.
Affected Systems and Versions
Exploitation Mechanism
Attackers with higher privileges can exploit the vulnerability to access directories storing executable files, leveraging authenticated users' write permissions to run unauthorized code with local administrative privileges.
Mitigation and Prevention
To address CVE-2018-14787, users and organizations should take immediate steps and implement long-term security practices to mitigate risks and enhance system security.
Immediate Steps to Take
Long-Term Security Practices
Patching and Updates